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Most scientific research is conducted properly and reported
honestly but a few authors invent or manipulate data to reach
fraudulent conclusions. Other types of misconduct include de-
liberately providing incomplete or improperly processed data,
failure to follow ethical procedures, failure to obtain informed
consent, breach of patient confidentiality, improper award or
denial of authorship, failure to declare competing interests, du-
plicate submission and plagiarism. Editors, peer reviewers and
publishers may also act wrongly. Good practice guidelines are
available from the International Committee of Medical Jour-
nal Editors (The Vancouver Group) and the Council of Scien-
ce Editors, amongst others. The Committee on Publication Et-
hics provides flowcharts to assist editors deal with authorial
misconduct. Examples are provided of cases involving epi-
demiological or public health research, reported to COPE over
the last 9 years. Suggestions are offered as to how miscon-
duct might be handled in future.
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Resumen
Aunque la mayor parte de la investigación científica se rea-
liza y comunica de manera honesta, algunos pocos autores
inventan o manipulan los datos para obtener conclusiones frau-
dulentas. Hay, además, otros tipos de malos comportamien-
tos, como proporcionar deliberadamente información incom-
pleta o mal procesada, vulnerar la confidencialidad de los
pacientes, atribuir o denegar improcedentemente la autoría,
no declarar algún conflicto de interés, publicar de forma du-
plicada y el plagio. Los editores y revisores externos también
pueden actuar erradamente. El Comité Internacional de Di-
rectores de Revistas Médicas (el Grupo de Vancouver) y el
Consejo de Editores Científicos han elaborado guías de buena
práctica. El Comité de Ética en Publicación proporciona dia-
gramas para ayudar a los editores a afrontar los casos de mal
comportamiento. En este trabajo se comentan algunos casos
prácticos de mala práctica en investigación en epidemiología
y salud pública de entre los abordados por el Comité de Ética
de publicación durante los últimos 9 años. Se presentan ade-
más sugerencias para tratar estas situaciones en el futuro.
Palabras clave: Malas prácticas. Ética. Publicaciones. In-
vestigación.
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Introduction
Rightly, the public expects scientists, resear-chers, clinicians and journal editors to be honestand trustworthy. Failure to live up to these ide-als can result in science being corrupted, pa-
tients harmed and financial sponsors deceived. While
the majority of research is conducted properly and re-
ported honestly, a depressing series of scandals shows
that there is a dishonest minority. In the worst cases, data
have been invented or manipulated to reach fraudulent
conclusions. But there are also lesser or more subtle de-
grees of scientific and publication misconduct. Those most
frequently encountered are listed in table 1.
Misconduct by editors, publishers 
and peer-reviewers
Authors are not the only ones who may be guilty of
misconduct. Editors, publishers and peer reviewers also
have responsibilities: for example, peer reviewers have
a duty of confidentiality pre-publication; they have a duty
not to allow professional or personal jealousy or rivalry
to influence or determine the advice they offer editors;
and they have a duty not to cause undue delay to the
processing of a submitted paper
Editors have a prime duty to their readers to main-
tain the integrity of the scientific record. This must take
precedence over their other duties, for example, making
sure their journal is readable and profitable (or, at least
not a financial burden for the society, academic institu-
tion, governmental body or publisher to whom they are
responsible). Therefore, they should follow good prac-
tice guidelines, such as those published by the Inter-
national Committee of Medical Journal Editors (ICMJE)
or the Council of Science Editors (CSE)1,2. Important
functions include correcting significant inaccuracies or
misleading reports by publishing corrections; ensuring
that proper ethical standards have been followed in the
conduct of research or clinical practice forming part of
submitted or published papers and paying strict regard
to patient confidentiality.
Editors can access advise from the Committee on
Publication Ethics (COPE) by way of flowcharts devi-
sed from the organisation’s experience over 8 years of
handling allegations of misconduct3. If a satisfactory ex-
planation cannot be supplied by authors, then editors
should normally report any reasonable concerns about
research misconduct to their institution(s) or those who
funded their study so that they can investigate and pu-
blish a notice of concern where the initial case looks
strong, followed by retraction when there is a finding of
fraud or a major error which, if left to stand, would sig-
nificantly distort the scientific record.
Editors and their publishers must make sure that their
journal is open and transparent in its instructions to aut-
hors (advice to contributors), especially with regard to
describing the peer review process as well as its defi-
nitions for authorship and requirements for declaration
of competing interests. They should have a well defi-
ned appeals procedure and an independently supervi-
sed complaints process.
Publishers, themselves cannot escape responsibi-
lity, if only because they may be required to investiga-
te and adjudicate on complaints against editors or edi-
torial boards. Some publishers have accepted that
responsibility. For example Wiley Blackwell provides a
set of ethical guidelines which it expects its journal edi-
tors to follow. Additionally, publishers should not attempt
to interfere with editorial freedom unless there are ex-
ceptional circumstances whereby an editorial board or
other responsible body produces cogent evidence that
an editor has misused that freedom.
Types of misconduct
Submission of fraudulent data
The extent of fraudulent research data is not known,
although many experienced editors believe that undis-
covered fraud is much more common than is supposed.
It is rarely easy to detect. An editor or associate editor
processing a paper may be suspicious that the results
are «too good to be true» but without specific experti-
se in the topic, he or she cannot be certain. Statistical
analysis of a paper will sometimes demonstrate that data
must have been manipulated. Likewise, reviewers so-
metimes express concerns about the honesty of a paper.
There have been numerous high profile cases of frau-
dulent data being presented. Most dramatic, perhaps,
was the claim of Professor Hwang Woo-suk of Seoul
National University that his team had created a cloned
human embryo from which it had extracted stem cells.
A major scandal involved Schön, whose research
on molecular scale electronic devices and induced su-
perconductivity in carbon «buckyballs» led to a series
of papers in Nature and Science which are now
known to contain data which were fabricated and mis-
represented.
Fraudulent papers may corrupt future research by
others as they continue to be cited (sometimes even after
they have been exposed). For example, a randomised
controlled trial concluding that a year of a low fat, fibre-
rich diet almost halved the risk of death from all cau-
ses4 had been cited 225 times by 2005 and included in
various guidelines, according to White5. In her paper,
she detailed the doubts expressed repeatedly by re-
viewers and editors. These led to mounting concerns
over other publications by the senior author, followed
by various inconclusive investigations and the ultimate
decision by the then editor of the BMJ, Richard Smith,
to publicise the entire history of the matter.
Table 1. Categories of scientific and publication misconduct
reported to the Committee on Publication Ethics (COPE) 
from 1998 to date
Carelessly or deliberately permitting basic faults in study design, performance 
or documentation which may prejudice the findings
Failure to follow accepted ethical procedures when involving live subjects 
(animal as well as humans), such as conducting experiments on human
subjects without properly informed consent or on animals without regard to
national regulations
Breaches of patient confidentiality or failure to obtain informed consent to take 
part in research (or for permission to submit case reports)
Inadequate or partial disclosure of how data were obtained and analysed with 
explanation for any exclusions
Electronic manipulation of images in such a way as to significantly change how 
they are interpreted
Improper award of authorship: all authors should have made significant 
contributions to the conception, design, analysis or reporting of the study 
and no such author may be excluded from final attribution
Failure to declare any competing interest, especially financial, which might bias 
a study’s conclusions or lead readers to doubt the conclusions
Attempts at redundant or duplicate publication
Breach of copyright and plagiarism
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In February 2005, the editor of Nutrition retracted a
paper by the Canadian researcher RK Chandra that it
published in 2001. This randomised controlled trial de-
clared that cognitive function in elderly people was im-
proved by provision of certain vitamins and trace ele-
ments in their diet. Grave doubts were then expressed
about a similar paper published in The Lancet: more than
10 years earlier which had been cited over 300 times6.
It is likely that many similar frauds are perpetrated,
often as part of a research project of lesser significan-
ce so that suspicions are not aroused. For example, one
editor was surprised to receive a paper detailing a po-
pulation survey in which data were collected 18 months
apart from the same 15,000 patients living in a parti-
cular area. Almost 100% follow-up was achieved des-
pite his knowledge that natural turnover by death, mo-
ving to another address or simple failure to cooperate
with a trial not funded to seek out non-respondents was
unlikely to reach a follow-up rate greater than 60%.
Publication of fraudulent research, apart from being
intrinsically dishonest, may distort the scientific record,
divert resources to projects doomed to failure as they are
predicated on the false data and, ultimately harm patients.
Countries have various systems to deal with fraud: for-
mal governmental mechanisms exist or are being deve-
loped in Australia, Canada, Denmark, Finland, Germany,
Norway, Sweden and the USA. In other countries indivi-
dual institutions may assume responsibility. Regulatory
bodies may become involved, not as primary investiga-
tors but to decide upon sanctions. For example, in the
UK, over the last 10 years, the regulatory body for me-
dical practitioners, the General Medical Council has char-
ged 20 doctors with fraud when conducting research –
often related to inserting non-existent patient data in a
medication trial–. For example, in 1997 a former secre-
tary of the Royal College of Physicians in Edinburgh was
erased from the medical register (thus removing his right
to practice medicine in the UK) for conducting a 15 month
long sham drug trial7 (case report 1).
Incomplete or improperly processed data
The reliability of the scientific record can be distur-
bed by conduct far short of fraud. For example, it is com-
monplace that inconvenient data are sometimes ex-
cluded from a study or that the most advantageous
statistical analysis is performed, especially if the results
can be used, for example, to increase prescribing rates
or enhance the chance of further research funding8.
Even with full disclosure, publication bias can dis-
tort the record when it results in a greater likelihood that
positive studies will be published and negative studies
rejected. Of course, this form of misconduct is as much
the responsibility of editors as it is that of authors. One
systematic review of studies comparing methodologi-
cal quality and outcome according to the source of fun-
ding showed that research sponsored by pharmaceu-
tical companies is less likely to be published than that
funded otherwise, that company sponsored research is
not of lower quality and that findings are more likely to
be favourable to the product investigated (OR = 4.05;
CI, 2.98-5.51)9. This begs the question of where are the
negative studies? Hopefully this form of manipulation
will be lessened by the recently adopted requirement
for trial registration which might allow future investiga-
tors to uncover unpublished trials for inclusion in sys-
tematic reviews and meta-analyses.
Reporting guidelines are available for many different
kinds of study. Not all journals require adherence but good
practice implies that authors have taken account of the cri-
teria within these guidelines. For example, when reporting
observational studies in epidemiology, authors are advi-
sed to follow the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) guidelines10;
meta-analyses are covered by the Meta-analysis of Ob-
servational Studies in Epidemiology (MOOSE) guidelines11.
Key requirements for all research papers include the
following: all sources and methods used to obtain and
analyse data, including electronic pre-processing,
should be fully disclosed; methods of analysis must be
explained and/or referenced; post hoc analysis of sub-
groups is acceptable so long as it is disclosed; discus-
sion sections should always mention how issues of pos-
sible bias have been addressed.
In basic science, as opposed to epidemiology and most
clinical research, an emerging problem is that of the im-
proper manipulation of images. Computer programmes per-
mit images to be sharpened, the colours changed or the
boundaries altered. Questions may arise as to how ex-
tensive this manipulation is permissible before the data
should be regarded as corrupted12 (case report 2).
Breaches of confidentiality and patient/subject consent
ICMJE guidelines state that all patients have a right
to privacy, which should not be infringed without infor-
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Case report 1
A reviewer informed a journal editor that the design of a population-based 
survey was flawed and he was convinced the survey could not have been
carried out as reported because the follow-up rate was impossibly high and he
doubted the authors had the financial resources to have undertaken a study
that involved collecting data in several countries. He had scanned Medline
and found 3 other studies with similar authorship, each with a similar protocol
but different populations, which seemed to him equally unlikely. Neither the
authors nor the head of their institutions responded to letters of enquiry from
the editor.
Source: Committee on Publication Ethics (http://www.publicationethics.org.uk/cases)
med consent. It adds that identifying details should be
omitted if inessential. Journal editors vary in how clo-
sely they follow this guidance. For example, the BMJ
group of journals states that consent must have been
obtained to publish material about a patient if there is
any chance they might be identifiable. An exception may
be made if the author has attempted to contact the pa-
tient but found it impossible, for example if either has
moved or if the former can no longer access caseno-
tes. Even then the journals demand that the public in-
terest in publishing the study must outweigh any pos-
sible harm that might befall patients if they are
identified.
This can pose problems, such as how to disguise pho-
tographs to make them unidentifiable. Many journals are
now placing their historic archives on-line; in previous
years, sensitivities were not so great so patient identifi-
cation was common. Should publishers remove identif-
ying data that is, for example over 50 years old?
An even more difficult question is how many patients
may be in a case series for there to be a real risk of
identification. For example, an author submitted a
paper detailing the histories of nine babies whom he be-
lieved had been suffocated by an abusive parent. The
text showed that only 3 had been found guilty in a court
of law so their actions were on public record. Unsur-
prisingly the author had not sought permission for pu-
blication from the other 6 whom he suspected. Since
the author had an appointment at just one hospital, any
reader could identify the area of the country where the
subjects lived, while from the text he could impute the
children’s ages, the period of time when the events oc-
curred and certain unusual features in their personal in-
formation. One journal editor to whom the paper was
submitted decided there was a risk of identification; an
editor of the next journal approached agreed but deci-
ded the public interest in the information being made
available outweighed any harm that might accrue to the
families involved. It must be doubtful, however, whet-
her he took into account the legal risks involved in po-
tentially defaming the individuals concerned.
Editors and peer reviewers should understand also
that submitted papers remain confidential until publis-
hed. Reviewers should not pass on papers to others to
read without the editor’s permission, reveal details, use
information in lectures nor use the pre-publication data
to inform their own research. Editors are in the same
position and must make sure that their instructions to
peer reviewers are clear about these matters.
Perhaps the most expensive example of a reviewer’s
breach of confidentiality was when Cistron Biotechno-
logy of New Jersey, USA alleged that a reviewer cho-
sen by Nature, who was an employee of Immunex Cor-
poration of Seattle, purloined a valuable DNA sequence
from the unpublished paper he had been asked to re-
view. Both companies sought patent rights to the se-
quence. The case was settled on the Courthouse steps
when Immunex agreed to pay US$ 21 million to Cistron
and transfer its patents13.
Authors and editors must also take care that proper
consent was given for the original study. In general, this
task is undertaken by the authors stating that local et-
hical committee or institutional review board (IRB) con-
sent was applied for and given. Problems may arise for
editors when considering papers from countries which
may not yet have high-quality IRBs. Many editors will
decline to process such papers but others may be less
restrictive. Once again, it is the responsibility of editors
and publishers to make sure potential authors are in-
formed of the journal’s policy in this respect.
Authors will sometimes claim that IRB approval was
unnecessary because the study in question represen-
ted a report or audit of normal clinical practice. The ques-
tion may then arise as to where the boundary lies bet-
ween research and practice, especially when considering
studies from tertiary or quarternary specialist centres.
Even where IRB approval has been granted, editors
may reserve the right to make their own decision as to
the ethics of the research presented. After all, IRBs them-
selves may not behave ethically (case report 3).
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Case report 2
An editor was told that a series of papers from a high profile researcher might be 
fraudulent and that the subjects described might not have existed. An
independent epidemiologist and a statistical adviser were asked to review the
published papers and two awaiting publication. Both experts doubted the truth
of the work and the author was asked to provide the original data. This arrived
in a large box, written in pencil: entering them into a computer proved time-
consuming and expensive. The statistician had other work to do but eventually
reported that the data in the one paper he had analysed was probably
fraudulent. The author appeared to be head of the institution where he worked.
He did not reply to the editor’s questions. The national body in his country
which seemed to be the regulatory authority stated that it did not have
jurisdiction and referred the editor back to the institution. Little progress was
made over several years.
Source: Committee on Publication Ethics (http://www.publicationethics.org.uk/cases)
Case report 3
A group of researchers were conducting a study of whether women aged 
65-69 would accept screening for breast cancer. They planned to invite
women for screening in the same way that they invite younger women as part
of normal public health practise. The women will, of course, consent to be
screened but would not be told they were part of a research study as the
authors feared that this knowledge might provoke some of them not to answer
some of their questions. The editor informed the authors he would consider a
submitted paper only if the women were told they were part of a survey.
Source: Committee on Publication Ethics (http://www.publicationethics.org.uk/cases)
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Authorship issues
The ICMJE criteria for authorship state that all per-
sons designated as authors should qualify and each
should have participated sufficiently to take public res-
ponsibility for the contents1. An individual cannot be in-
cluded if he or she has not made a substantial contri-
bution to the conception or design of the trial; or to the
analysis and interpretation of the data; or to drafting the
article or revising it for intellectual content as well as final
approval. Again, journals should make clear in their ins-
tructions to authors what criteria they will apply when
assessing authorship (or contributorship, as some jour-
nals prefer) (case report 4).
Where an editor is made aware of disputes betwe-
en authors or groups of authors pre-publication, it is best
not to accept the paper until the protagonists have set-
tled their dispute. An exception might be when it is alle-
ged that a particular author is deliberately refusing to
co-operate in order to prevent or delay publication, per-
haps because of personal antipathy to one or more co-
lleagues.
The practice of honorary authorship has a long his-
tory, with authors named who do not meet the criteria
for authorship, for example heads of department who
have had no involvement in the particular research study
other than as an employer. A less frequent but still unac-
ceptable practice is that of ghost authorship, where an
individual who has qualified for authorship does not ap-
pear on the list of authors. One survey of correspon-
ding authors of papers published in 3 large-circulation
general journals and 3 specialist journals showed that
19% of articles had honorary authors and 11% ghost
authors14.
Many researchers and clinicians, however compe-
tent and distinguished, do not have literary or journa-
listic skills so may employ a staff writer, particularly com-
mon in large pharmaceutical company trials. Where a
medical writer has assisted they should be mentioned
in the paper’s contributorship statement and whether or
not he or she was paid should be mentioned in the sta-
tement on funding. The European Medical Writers As-
sociation (EMWA) has published guidelines which in-
clude a statement on such writers professional
responsibilities in ensuring that papers they write are
scientifically valid and produced in accordance with ge-
nerally acceptable ethical standards15.
Competing interests
We all have competing interests of some sort. By
having their papers published, authors enhance their cu-
rriculum vitae (résumé), become stronger candidates
for appointments and consequently increase their in-
come. Editors may favour certain topics over others be-
cause of belief they might catch the eye of the public
media and so lead to the editor’s name being better
known to the profession and the public. Reviewers may
be tempted to allow personal grievances or favours to
affect their judgement. Good practice demands that, as
far as possible, competing interests are subsumed by
the need to be objective and fair.
In defining what might be a significant competing in-
terest, one suggestion is that if it were later revealed,
readers might feel misled or deceived. The most serious
is likely to be financial or commercial but personal and
political conflicts can affect judgement. Financial inte-
rests may include being paid by the sponsor of a re-
search project to undertake the work, or receiving reim-
bursement for lecture or travel. Holding stock or share
ownership, consultancies and holding or seeking patent
rights in any product or device can also be regarded as
a competing interest.
In 2001, Hussain and Smith16 sampled 3632 rese-
arch papers published in Annals of Internal Medicine,
Lancet, JAMA, New England Journal of Medicine and
BMJ between 1989 and 1999. They found that only 52
(1.4%) included a declaration of competing interest alt-
hough the situation had improved in the later years of
the survey. Nonetheless, such conflicts are common: Be-
kelman17 reported that 1 in 4 US researchers received
pharmaceutical company funding, and half disclosed re-
lated gifts. In his review of 789 papers in major medi-
cal journals, he found that 1 in 3 lead authors held sha-
res, patents, directorships or paid membership of
advisory boards.
The solution is straightforward: journals should re-
quire all authors to sign a declaration on submission of
any competing interest (and if they have none). It will
then be a decision of the editor as to whether this af-
fects the chances of acceptance and of the readers as
to whether it alters their view of a published paper’s con-
clusions. Editors and reviewers should also make it clear
if a competing interest may affect their work; it is bet-
Case report 4
A paper was accepted subject to revision. The authors had interrogated 
a national data set recording certain patients’ deaths and medicine
prescriptions. The revised version did not contain the names of 2 original
authors from a government body holding the data but only the other 2, from a
university. The editor was contacted by a senior government official and the
head of a regulatory board, concerned about possible adverse results on
public health if the paper was misinterpreted by the national media as
suggesting certain drugs were dangerous. The editor persuaded the remaining
authors to modify their conclusions. He remained unsure as to whether he
should have rejected the revision as two authors were now ‘ghosts’ and
whether he had improperly succumbed to pressure and thereby improperly
pressured the remaining authors to alter their paper.
Source: Committee on Publication Ethics (http://www.publicationethics.org.uk/cases)
ter to decline to undertake a review or transfer a sub-
mitted paper to another member of the editorial team
if there is any risk of being perceived as biased (case
report 5).
Redundant and duplicate publication
Because of the professional necessity or importan-
ce of having one’s research published, authors may be
tempted to produce several papers from one dataset.
There may be good reasons for this, which do not re-
present publication misconduct in any way. The results
of a study may have different implications for differing
professional or specialist groups: for example, a study
on the long-term outcome of treatment of, say, myocar-
dial infarction may contain material relevant to cardio-
logists, pharmacologists, intensivists, nurses and psy-
chologists. In such circumstances it may be acceptable
to divide the data where some may be relevant only to
a particular readership because of the message it con-
veys. What matters is full disclosure, both at submission
and in citations. Authors should always make clear if a
contribution is part of a wider study and should include
with their submission any other published or submitted
paper depending on the same data set or patient group.
A study may, of course, be redundant before it starts.
Where a subject has been thoroughly and convincingly
elucidated, some find it questionable whether resour-
ces and, more importantly, the contribution of patients
or subjects, might be misused by repeating the study.
Researchers need to consider this before designing their
trial.
Any attempt at duplicate publication, that is sen-
ding the same or very similar findings from the same
study to more than one journal is misconduct. Firstly,
the second submission may involve intellectual theft
as the journal which first published the study may hold
copyright or a license which only allows the author to
use the material with permission. More importantly, du-
plicated papers may have a significant effect on sys-
tematic reviews and meta-analyses if the same data
are counted twice.
This was well illustrated in a systematic review by
Tramér et al18 of papers comparing the effectiveness of
intravenous ondansetron in preventing vomiting. They
found 16 unduplicated studies and 3 studies subject to
duplication (with 6 duplicates of the 3 studies). The cal-
culated number needed to treat (NNT) from the 16 un-
duplicated papers was 9.5 while, from the 3 papers
where the data were published more than once, it was
3.9. Combining all 19, the NNT was 4.9. The true NNT
was 6.4.
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Case report 5
A journal published a paper on passive smoking in which the authors failed 
to declare financial support from the tobacco industry. Although the authors
responded to the editor’s enquiry by admitting funding from one source, he
considered this insufficient and wrote an editorial detailing the extensive
involvement of the research group with the industry. He was reluctant to
publish their letter of response without further disclosure and refused to
consider a second submitted paper. Eventually it became clear that the senior
author had a consultancy with a tobacco company, for which he had lobbied
outside his home country. COPE advised the editor to publish the entire
history of the case and report the author to his country’s research integrity
body. Subsequently the editor gave evidence at the author’s action for libel
against another research group. During the hearing evidence of data
tampering came to light and the Court decided the author had been involved
in «unprecedented fraud».
Source: Committee on Publication Ethics (http://www.publicationethics.org.uk/cases)
Table 2. Websites with advice and discussion of ethical issue in scientific publication
Institution Website
International Committee of Medical Journal Editors http://www.icmje.org/
Committee on Publication Ethics http://www.publicationethics.org.uk/
Office of Research Integrity http://ori.dhhs.gov/
Council of Science Editors http://www.councilscienceeditors.org/
World Association of Medical Editors http://www.wame.org/
Danish Committees on Scientific Dishonesty http://forsk.dk/
Deutsche Forschungsgemeinschaft (proposals for http://www.dfg.de/aktuelles_presse/reden_stellungnahmen/
safeguarding good scientific practice, in English) download/self_regulation_98.pdf
Swedish Medical Research Council http://www.vr.se/english
Canadian Guidelines on Ethical Conduct for Biomedical http://www.nserc-crsng.gc.ca/
Research Involving Humans
Indian Council of Medical Research http://icmr.nic.in/
UK Panel on Biomedical Research Integrity http://www.UKRIO.org.uk/
World Medical Association Declaration of Helsinki http://www.wame.com/
Bibliography on Scientific Fraud http://www.albany.edu/~scifraud/bibliography.htm
Reviewers and readers are often the first to disco-
ver duplication, more frequently now that electronic se-
arching is the norm. One or more authors may be una-
ware that a colleague has had the paper published
elsewhere. Editors have a duty to publish a notice of
withdrawal of the second publication and to request the
employer or funder of the corresponding author to un-
dertake an investigation.
Many editors are happy to accept papers which have
been published previously in another language, provi-
ded the original is clearly listed in the references. Edi-
tors may disagree about prior presentation at a scien-
tific meeting or on the website of an academic institution
(table 2). In both cases, editors rightly demand full dis-
closure in advance. This allows them to make an in-
formed decision on whether the value for readers, or
the public health generally, outweighs previous expo-
sure. Generally, prior publication in abstract form in con-
ference proceedings is acceptable but authors should
take care when publishing on-line; if the web version
can be accessed outside the institution it may be vie-
wed as having been published.
Editors also have differing approaches to prior an-
nouncement in the lay media of the results of a study.
Some will regard this as precluding acceptance in their
journal; most would be concerned only if the media ar-
ticle gave a detailed description of the methods and/or
results rather than some general conclusions (case re-
port 6).
Plagiarism
Using the words or ideas of another person without
attribution represents intellectual theft, or plagiarism. Aut-
hors must realise that, when quoting the work of others,
they must make it clear and provide a reference to the
original material. With the advent of electronic searching
and the increasing use of systematic reviews, plagia-
rism comes to light more easily in the past19. It is also
possible to self-plagiarise; for example, it is not unknown
for authors invited to write a review article to ‘recycle’
their own previous work. In doing so it would be more
honest to advise the editor in advance that they have
done so. Many editors would regard this as improper,
especially if the author has been commissioned (and
paid) for writing a review.
Unfortunately, it seems to be a worldwide pheno-
menon that school and university students are using ‘cut
and paste’ techniques from the internet. This may carry
over into their professional careers so that when they
are accused of plagiarism they may not realise that they
have done wrong. COPE has had the experience on se-
veral occasions of junior authors, often from the deve-
loping world, stating that they had been taught to write
in that way. In dealing with plagiarists, the experience
of the author is an important criterion to take into ac-
count (case report 7).
Conclusions
There is little doubt that there is growing awareness
that science needs policing. Much of the impetus has
come from individual ‘whistleblowers’, often junior co-
lleagues who may have to put their own careers at risk
by laying information against a senior member of their
department. Journal editors, with help from reviewers
and readers, are gradually finding their voice. But it is
not enough to leave the handling of publication mis-
conduct in the hands of ad-hoc bodies such as ICJME
and COPE. Governments, universities, research coun-
cils, the pharmaceutical industry and other funding bo-
dies all have a duty to ensure the integrity of the scien-
tific record. Some countries have formalised their
response, for example the US Office of Research In-
tegrity, albeit it can deal only with federally funded re-
search, while national mechanisms exist or are in de-
velopment in Canada, Denmark, Finland, Germany,
Norway, Sweden, Australia and the UK. Many univer-
sities have sophisticated procedures to deal with alle-
gations of research misconduct while others are accu-
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Case report 6
An identical paper was submitted to 2 journals: both contained a declaration that 
it had not been submitted elsewhere. The corresponding author cited two of
his previous papers within his submission; a PUBMED search showed these
were duplicates of each other. Both journals withdrew the paper from their
review process. The authors apologised for «inattentiveness and hurry» and
«circumstances beyond our intention». They did not explain their previous
duplicate publications. The editor wanted to report matters to the author’s head
of department but he was listed as a co-author. COPE advised the editor to
request the head of the institution to conduct an investigation.
Source: Committee on Publication Ethics (http://www.publicationethics.org.uk/cases)
Case report 7
A reviewer pointed out that a review paper (with 3 authors) contained entire 
paragraphs, without attribution, from two published articles which he had
written himself. The corresponding author replied that the review article had
been written by a co-author whom he had never met. A second co-author was
on sabbatical leave but working in his department and had asked him to
review the article, comment upon it and act as corresponding author. This
«honorary» author accepted responsibility and apologised to the editor and
reviewer. COPE advised the editor to inform the head of the institution and
recommend a document about the responsibilities of authors be circulated to
all staff.
Source: Committee on Publication Ethics (http://www.publicationethics.org.uk/cases)
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sed of not doing enough20,21. There remains no agreed
set of sanctions beyond rejecting suspect manuscripts
or publishing retractions on those proved fraudulent.
Science has no borders and journals admit papers from
all over the world, often with co-authors attached to ins-
titutions in different countries. It is time for an interna-
tional consensus on dealing with misconduct. A star-
ting point might be the example of the speed and
efficiency with which the Norwegian authorities dealt with
the multiple fraudster, Jan Sudbo. In October 2005 he
published a paper in The Lancet22. Within weeks, the
Cancer Registry of Norway alerted authorities that Sudbo
could not have accessed data in their registry which for-
med a key part of his paper. In January 2006 an in-
vestigation commission was set up by the University of
Oslo and the Rikshospitalet-Radiumhospitalet, under the
chairmanship of the head of the clinical epidemiology
unit at the Karolinska Institute, Stockholm, Professor An-
ders Ekbom. In June 2006 the commission produced
its report23, arising from which many of Sudbo’s papers
were retracted, he resigned from his posts and had his
licences to practice medicine and dentistry revoked by
the Norwegian Board of Health. The report concludes
thus: «The research community must make an all-out
effort to make plain research’s traditional ideals of ho-
nesty, thoroughness, trustworthiness and openness».
And so it must, not just in Norway.
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